ImmuPharma (LON:IMM) Shares Down 21.1% - Should You Sell?

Key Points

• ImmuPharma's stock price fell by 21.1%, trading at GBX 11.76 after opening as low as GBX 10.80.
• The company reported a negative PE ratio of -1,446.18 and a negative return on equity of 131.41% for the last quarter.
• ImmuPharma is focused on developing peptide-based therapeutics, with its lead program, P140 (Lupuzor™), aimed at treating Lupus and potentially other autoimmune diseases.

ImmuPharma plc (LON:IMM - Get Free Report)'s stock price was down 21.1% during trading on Thursday . The stock traded as low as GBX 10.80 ($0.15) and last traded at GBX 11.76 ($0.16). Approximately 45,915,910 shares changed hands during mid-day trading, an increase of 438% from the average daily volume of 8,530,393 shares. The stock had previously closed at GBX 14.90 ($0.20).

ImmuPharma Price Performance

The firm's fifty day simple moving average is GBX 4.28 and its 200 day simple moving average is GBX 3.27. The company has a market capitalization of £62.47 million, a PE ratio of -1,404.49 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. On average, equities research analysts anticipate that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.